The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms MENSCH
- 07 Jun 2017 Biomarkers information updated
- 15 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 15 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.